Corcept Therapeutics' ALS drug fails in mid-stage trial
Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...
Business Wire9h
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe e ...
Hosted on MSN18h
Critical link between protein and ALS disease offers new hope
Scientists are uncovering new insights into the mechanisms driving neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These fatal diseases ...
UnitedHealthcare CEO’s shooting opens a door for many to vent frustrations over insurance
The slaying has unleashed a wave of public feeling — exasperation, anger, resentment, helplessness from Americans sharing ...
Hosted on MSN18h
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug
Qure N.V. QURE surged 109.7% after it announced reaching alignment with the FDA on key elements of an accelerated approval ...
Research reveals possible link between protein G3BP1 and amyotrophic lateral sclerosis
Researchers from the Structural Biology Brussels group at Vrije Universiteit Brussel (VUB) have uncovered a significant ...
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS
FDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY ALS ...
Business Wire5d
New Data Supporting a New Precision Medicine Approach for ALS Patients With GeNeuro’s GNK-301 Presented at the 35th International Symposium on ALS/MND
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on addressing the factors driving the ...
Medical News Today13d
What to know about amyotrophic lateral sclerosis MRI
MRI is a diagnostic test that doctors use to diagnose and track the progress of amyotrophic lateral sclerosis (ALS). ALS is a progressive disease that damages nerve cells in the brain and spinal cord.
Taiwan News9d
Amyotrophic Lateral Sclerosis Treatment Market Size, Share, Analysis, Top Industry Players and Forecast 2025-2033
The global amyotrophic lateral sclerosis treatment market size was US$ 637.2 million in 2021. The global amyotrophic lateral sclerosis treatment market is forecast to grow to US$ 918 million by 2030, ...